Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Data suggests that patients with CLL who are on venetoclax plus obinutuzumab and reach undetectable MRD may be able to discontinue therapy early.
Testing for measurable residual disease (MRD) through next-generation sequencing (NGS) with clonoSEQ revealed zero to one cell per million in the blood.
Measurable residual disease (MRD) testing measures the amount of cancer cells that are present in blood or bone marrow at the time the sample was collected.
It’s been a month since my last post on progress in my trial of epcoritamab, a bispecific T cell engager (BiTE) for my chronic lymphocytic leukemia.
MRD guided acalabrutinib, venetoclax and obinutuzumab led to an 88% progression free survival rate in relapsed / refractory chronic lymphocytic leukemia.
Measurable residual disease (MRD)-guided treatment of CLL with ibrutinib plus venetoclax significantly increased time in remission.
I found out last week that I am not only in a complete remission, but also there was no measurable CLL in my peripheral blood done by flow cytometry, down to 1 in 10,000 cells
CLL Society has put together a learning activity that will help those with CLL / SLL learn about the role of MRD testing, gain an understanding of how it can be used as part of your disease management plan, and empower you to discuss its potential use with your healthcare provider.
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who achieved undetectable measurable (or minimal) residual disease (uMRD) after fixed-duration ibrutinib + venetoclax treatment continue to have excellent outcomes four years after stopping initial therapy. The results of this study suggest that if patients achieve uMRD remission, it is safe to stop treatment.
One click to our most popular content.
